| Research object | Methods | Main results | Reference | |
|--|--|--|-----------|--|
| CRL1739 cells, human GC | Immunoprecipitation and immunoblot analysis | IL-4R α and IL-2R γ -common chain were expressed in CRL1739 cells and GC | 42 | |
| specimens | minunobiot analysis | specimens. | | |
| CRL1739 cells | Dratain comthesis accord | • | 39 | |
| CKL1739 cells | Protein synthesis assay using [³H]leucine | One chimeric protein composed of IL-13 and Pseudomonas exotoxin was highly | 39 | |
| | using [³ 1]leucine | cytotoxic. | | |
| HTB-135 cells | Coll Cuolo Apolucio Vit | , | 43 | |
| 111D-155 Cells | Cell Cycle Analysis Kit (Becton Dickinson), FCM | IL-4 inhibited proliferation of GC cells by | 43 | |
| MVNI 45 and ACS | | blocking cell cycle progression. | 40 | |
| MKN-45 and AGS cells | Boyden chamber assays | CHI3L1 secreted by M2 macrophage could | 40 | |
| cens | | promote the metastasis of GC cell lines by | | |
| | | binding to the IL-13R α 2 chain. | 22 | |
| AGS and MGC308 | Co-immunoprecipitation | | | |
| cells; 100 human GC tissues | assay, | $13R\alpha^2$ in GC cell lines. CHI3L1 was | | |
| | immunofluorescence, IHC | upregulated during GC development. | 4.4 | |
| HTB13, CRL1863, | Standard [³ H]thymidine | IL-4 could inhibit the growth of GC cells and | 44 | |
| CRL1739, and | incorporation | this effect was positively related with IL-4R | | |
| KATO III cells; one primary GC cell line | proliferation assay, FCM | expression level of the respective cell lines. | | |
| 507 GC patients | Tissue microarray and | Overexpression of IL-13R α 2 chain in GC | 15 | |
| I I I I I I I I I I I I I I I I I I I | IHC | tissues was associated with poor prognosis after gastrectomy. | | |
| 30 biopsies from | IHC | The expression of IL-4 was higher in stages I | 46 | |
| GC patients | | and II GC than in stages III and IV. | | |
| 17 patients and 30 | sandwich ELISA kit | Serum IL-4 levels in patients were | 45 | |
| healthy controls | (Affymetrix | significantly higher than in controls. | | |
| - | eBioscience) | | | |
| 25 patients and 54 | Bio-Plex human cytokine | Cytokine levels of IL-4 and IL-13 in patients' | 41 | |
| healthy controls | assay (Bio-Rad) | plasma were significantly higher than in | | |
| | | controls. | | |

Supplemental Table 1. Effects of IL-4/IL-13 in GC

Cell lines mentioned in this table are all human GC cell lines unless otherwise indicated. GC: gastric cancer; IHC: immunohistochemistry; CHI3L1: Chitinase 3-like protein 1; ELISA: enzyme-linked immunosorbent assay.

| Research object | Methods | Results | Reference |
|------------------|-------------------------------------|--|-----------|
| LS174T and HT- | WB, RT-PCR | IL-4 and IL-13 increased mucin 2 expression in | 48 |
| 29 cells | | LS174T cells, but not in HT-29 cells. | |
| HT-29 cells | WB, RT-PCR, Northern | IL-13 could inhibit the macroautophagy pathway | 49 |
| | blot; L-[¹⁴ C]valine | via the activation of the class I PI3K. | |
| HT-29 cells | WB; [¹⁴ C]valine | Overexpression of tumor suppressor phosphatase | 50 |
| | | and tensin homolog could counteract the IL-13 | |
| | | down-regulation of macroautophagy. | |
| Colo201 and | Protein synthesis assay | One chimeric protein composed of IL-13 and | 39 |
| Colo205 cells | using [³ H]leucine | Pseudomonas exotoxin was highly cytotoxic. | |
| HT-29 and | WB | IL-13 induced phosphorylation of JAK2, JAK1, and | 51 |
| WiDr cells | | Tyk2. IL-13 and IL-4 could induce phosphorylation | |
| | | of STAT6. | |
| HT-29, CaCo-2, | FCM, Northern blot, IP | IL-4 and IL-13 could upregulate expression of CD44. | 52 |
| DLD-1, T84 cells | | | |
| RKO and SW480 | MTT, transwell assay, | Propofol suppressed cell proliferation and IL-13 | 54 |
| cells | RT-PCR, WB, | induced EMT in CRC cell lines. Propofol suppressed | |
| | luciferase assay | IL-13/STAT6 signaling pathway. | |
| HT29, SW480, | WB, PCR, transwell | IL-13 promoted EMT and aggressiveness of CRC | 55 |
| Caco2 cells | assays, ChIP, luciferase | through IL-13R α 1/STAT6/ZEB1 pathway. | |
| | reporter assay | | |
| HT-29, WiDr, | MTT assay and | In HT29, WiDr, LS411N, LS513, LS1034 cells, IL-4 | 65 |
| SW1116, Co-115, | incorporation of [3H]- | inhibited proliferation; in CO-115 and SW1116 cells, | |
| LS411N, LS513 | TdR; FACS; northern | no difference. Three cell lines (HT29, LS1034, WiDr) | |
| and LS1034 cells | blot; biotin-labeled IL- | exhibited relatively high density of the IL-4R and 4 | |
| | 4 binding studies | (Co-115, LS4llN, LS513, SW1116) had lower density. | |
| HT-29 and | Cell proliferation was | IL-4 and IL-13 increased nicotinamide adenine | 12 |
| DLD-1 cells | determined by | dinucleotide phosphate oxidase 1-related | |
| | counting the cells. | proliferation. | |
| HT-29 and | [³ H]-TdR incorporation | IL-4 inhibited cell growth of CRC cells. | 69 |
| WiDr cells | assay | | |
| HT-29 cells | Cell counting or | IL-4 inhibited the growth of HT-29 cells. | 70 |
| | colorimetric MTT | | |
| | assay. | | |
| HTB 38 cells | Human tumor cloning | IL- 4 showed antiproliferative activity. | 71 |
| | assay | | |
| LS531 cells | [³ H]-TdR incorporation | IL-4 inhibited cell proliferation. | 73 |
| | assay | | |
| HT-29 cells | FACS. PBMCs were | IL-4 significantly suppressed IL-12, IL-2 and IFN- | 75 |
| | separated from a | alpha enhanced ADCC against HT-29 cells. | |
| | patient with chronic | - | |
| | lymphocytic leukemia. | | |

Supplemental Table 2. Effects of IL-4/IL-13 in CRC cells

| SW948 cells, human PBMCs, mAb 17-1A | PBMCs were incubated for 0-24 h with IL-4 before ADCC assay | Pretreatment with 1 ng/ml IL-4 for 2 hours induced a significant increase in the ADCC activity of PBMCs. | 76 |
|--|---|--|----|
| LS174T cells; human peripheral monocytes | 24-h ¹¹¹ In-release assay was used to measure ADCC activity. | IL-4 and macrophage colony-stimulating factor had a synergistic enhancement effect of monocyte- mediated ADCC on LS174T cells. | 78 |
| HT-29 cells, PBMCs | Flow cytometric cytotoxicity assay | IL-4 decreased ADCC and reduced the IL-2, IL-12, and IFN-alpha-induced ADCC. | 79 |
| SW620 cells | ELISA | IL-4 sensitized SW620 cells to radiation by inhibiting NF-kappaB. | 80 |
| HT-29, LoVo and SW480 cells | Indirect immunofluorescence, FACS | IL-4 could decrease epithelial cellular adhesion molecule and Lewis ^Y expression in HT-29 and LoVo cells, but not in SW480 cells. | 81 |
| LS174T cells | Northern blot, RT- PCR, FCM | IL-4 inhibited the expression of stem cell factor and its receptor c-kit in LS174T cells. IL-4 could also inhibit stem cell factor-induced proliferation. | 82 |
| HRT18, H29/6 and HT115 cells | ELISA | The addition of IL-4 increased IL-8 release in HT115 cells, but not in HRT18 and H29/6 cells. | 83 |
| Colo205 cells | FCM, RT-PCR analysis | IL-4 inhibited cell-cell adhesion but not cell proliferation. IL-4 and IL-13 could down-regulate E- cadherin and carcinoembryonic antigen molecules. | 84 |
| Primary CRC cell lines CoSp, Cope, and CoDo; HT-29 cells | WB, RT-PCR, transwell assay | IL-4 was an inhibitor of hepatocyte growth factor and it could regulate hepatocyte growth factor- induced cell proliferation and other events of tumor progression. | 85 |
| WiDr and HT- 29 cells | [³ H]-TdR uptake studies, IP and WB, northern analysis | The addition of IL-4 phosphorylated JAK1, JAK2, and Tyk2, and activated JAK1 and JAK2. | 86 |
| Caco cells | RT-PCR, MTT assay, trypan blue test, ELISA | Anti-IL-4 antibody inhibited the growth of the Caco cells. Neutralizing of IL-4 increased the efficacy of chemotherapy and inhibited the CD133+ cells. | 88 |
| HT-29 and Caco-2 cells | RT-PCR, FCM, transwell migration assay | IL-4/Stat6 activities correlated with apoptosis and metastasis in colon cancer cells. | 89 |

Cell lines mentioned in this table are all human colon cancer cell lines unless otherwise indicated. CRC: colon and rectal cancer; WB: Western blot; RT-PCR: reverse transcription-polymerase chain reaction; PI3K: phosphatidylinositol 3-kinase; JAK: Janus kinase; STAT: signal transducer and activator of transcription; FCM: flow cytometry; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid; ChIP: chromatin immunoprecipitation; IP: immunoprecipitation; EMT: epithelial–mesenchymal transition; ZEB1: Zinc finger E-Box binding homeobox 1; FACS: fluorescence-activated cell sorting; IFN: interferon; ADCC: antibody-dependent cellular cytotoxicity; PBMC: peripheral blood mononuclear cell; PKH: Paul Karl Horan; ELISA: enzyme-linked immunosorbent assay; NF-kB: nuclear factor kappa-light-chain-enhancer of activated B-cells; EpCAM: epithelial cellular adhesion molecule.

| Research object | Methods | Results | Reference |
|--------------------------------|---|---|-----------|
| KM12, KM12C and | ELISA, WB, IHC, FCM | High expression of IL-13R α 2 in KM12 cells was | 13 |
| KM12SM cells, nude | | associated with liver metastasis in nude mice. | |
| mice and 80 CRC | | IL-13R α 2 overexpression in CRC tissues was | |
| patient tissues | | associated with later stages and poor prognosis. | |
| Tissues from 359 | IHC | High expression of IL-4, IL-4R, and IL-13R was | 47 |
| patients | | associated with a lower frequency of lymph | |
| | | node metastases. | |
| KM12SM, SW620, a | WB, IHC, IP, transwell | IL-13R α 2 induced activation of the FAK and | 11 |
| metastasis model of | assay | PI3K/AKT/mTOR pathways and this was | |
| nude mice | | mediated by FAM120A. | |
| SW480 cells and | WB, quantitative RT- | IL-13 induced the expression of 11β HSD2 in | 56 |
| murine CC cells | PCR, MTT assay, | CRC cells through IL-13R α 2 and promoted the | |
| CT26, murine liver | colony formation | malignancy of CRC. | |
| metastasis model | assay; nude mice | | |
| KM12SM, SW620, | Mass spectrometry | Protein tyrosine phosphatase-1B could mediate | 57 |
| RKO cells, mouse | analysis, WB, IP, MTT | IL-13-induced cancer cell proliferation, | |
| models | assays, FCM | migration, invasion and survival. | -0 |
| LS174T, LOVO, | ELISA, real-time PCR, | IL-4 and IL-13 both up-regulated the expression | 58 |
| SW480 and COLO | WB, IHC | of chemokine eotaxin-2 in LS174T and LOVO | |
| 205 cells; 25 CRC | | cells. | |
| patients | | The formation of CDC area many for most in | 50 |
| Mouse model of CRC | WB, IHC, MTT assay, Bio-Plex Pro Mouse | The formation of CRC was more frequent in | 59 |
| induced by injection | Cytokine 23-Plex Panel | obese mice than wild type mice. Silencing IL- | |
| of azoxymethane; HT29 cells | Cytokine 25-riex ranei | 13R α 1 inhibited IL-13-induced proliferation in HT29. | |
| Murine CRC lung | FCM, BALB/c mice | The development of lung metastases could be | 60 |
| metastasis model; | and CD1-knockout | significantly decreased by an IL-13 inhibitor, but | 00 |
| murine CC cell line | mice | not by inhibiting IL-4. | |
| CT26 | mille | not by minoring in 1. | |
| KM12SM and SW620 | Competition ELISA, | IL-13R α 2 D1 peptide inhibited migration, | 61 |
| cells, nude mice and | MTT assay, wound | invasion, and proliferation in metastatic CRC | • - |
| Balb/c mice | healing assay, | cells treated with IL-13. Nude mice treated with | |
| | transwell invasion | the enantiomer D-D1 peptide showed a | |
| | assay, FCM | significantly survival increase to metastasis. | |
| IL-4R α and IL-13 | IHC, case–control | Reduced IL-4R signalling increased CRC risk | 62 |
| transgenic mouse | epidemiology study, | but reduced tumor progression. It had no effect | |
| models, CRC | FCM, multiplex | on CRC mortality. | |
| patients and controls | immunoassay | - | |
| 241 patients with | ELISA | Patients with advanced stage of CRC had lower | 63 |
| CRC | | serum IL-13 levels. Low serum IL-13 was | |
| | | associated with poorer prognosis. | |
| | | | |

Supplemental Table 3. Effects of IL-4/IL-13 in CRC mouse models or patients

| Fecal protein from 20 CRC patients and 20 healthy controls | ELISA, bicinchoninic acid assay | The expression of IL-13 was significantly higher in CRC patients. | 64 |
|--|--|--|----|
| Murine CC cell line CT26 tumor-bearing mice | ELISA, quantitative RT-PCR | Protein levels of IL-4, and IL-13 were higher in the serum or the tumor homogenates of CT26 tumor-bearing mice. | 66 |
| Patients with metaplastic polyps, adenomas, or carcinomas | IL-4R was detected by IHC | The expression of IL-4R was positive in all polyps (5/5), adenomas (15/15) and in 40/45 carcinomas. | 67 |
| HCT116, HT-29, DLD-1, SW480, SW620, Caco2 and HCA7 cells; IL-4Rα - /- mice | MTT assay, RT-PCR, WB, FCM, immunostaining | IL-4R α expression promoted tumor growth in HCT116, HT-29, DLD-1, SW480, SW620, Caco2 and HCA7 cells, but IL-4 could only decrease apoptosis in HCT116 cells. | 68 |
| HCT116 and RKO cells; subcutaneous xenograft mouse models, 218 human CRC samples | WB, qRT-PCR, luciferase assay, chromatin IP assay, transwell invasion assay, IHC | IL-4 could promote EMT of HCT116 and RKO cells through E2F1/SP3/STAT6 axis. Analysis of clinical CRC samples showed a positive correlation between E2F1, SP3 and STAT6. | 74 |
| HT-29 cells and a metastasis model in nude mice | FCM, northern blot | IL-4 changed the expression of integrin and decreased the lung-colonizing ability of HT-29 cells. | 87 |
| Primary human CC cells; nude mice | FCM, IHC, immunofluorescence analysis, WB | CC growth was dictated by stem-like cells which were resistant to chemotherapy due to autocrine of IL-4. | 14 |
| CC-bearing mice | qRT–PCR, ELISA, immunofluorescence | Addition of IL-4 improved muscle function and lifespan of CC-bearing mice. | 90 |
| HCT116 cells; NOD/SCID mice; CC tissues from 40 patients | RT-PCR, IHC, WB, FCM, transwell migration assay | Over-expression of IL-12 could inhibit the expression of IL-4 and STAT6 in CSCs and inhibit their survival. | 91 |
| MC38 murine CC cell line, mice | IHC, 4-h 51Cr-release assays, female C57BL/6 (B6) mice | IL-4 combined with CpG oligonucleotide could suppress tumor growth by activating Th1-type immune responses. | 92 |
| Murine CC cell line CT26 tumor-bearing mice | IHC, FCM, qRT-PCR | An IL-4R α aptamer-liposome-CpG oligodeoxynucleotide delivery system had enhanced anti-tumor activity. | 93 |
| Murine CC cell line colon 26; BALB/c mice | IL-4 overexpressing colon 26 cells; ELISA; 51Cr release assays | Overexpression of IL-4 in colon 26 cells could induce local tumor killing as well as systemic immunity in mice. | 94 |
| MC38 murine CC cell line, female B6 mice | Subcutaneous tumor models of mice; 4-h 51Cr-release assays | IL-4 overexpression MC38 cells promoted a tumor-specific Th1-type response in B6 mice. | 95 |

| 77 CRC patients, 70ELISASerum IL-4 levels of the patients were significantly higher than the control group.97105 CRC patientsELISAThe serum levels of IL-4 can be used as a marker of pre-invasive to invasive CRC.9810 CRC patients with 5 healthy controlsFlow cytometric immunophenotypingFligher serum levels of IL-4 were found in patients than controls. The CD8+ cytotoxic cells might be negatively regulated by serum IL-4.9999 CRC patients and 107 healthy controlsELISAIL-4 serum levels were significantly higher in patients.101107 healthy controlsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue. Multiplex kit101Primary CC cellsRT-PCR, WB, FCM, transvell assay, FCM, isolated from 18 primary human CCTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary num metastatic tumors if orm of uCR with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104Primary CR cells, noiceImmunofhuorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity in vitro.10541 metastatic CRC patientsBio-Plex human cytokine multiplex kits (Bio-Rad ILc.), FACS, Him dylate synthase poly-epitop-peptide infiltrating lymphocytes was associated with better prognosis.10741 metastatic CRC patientsBio-Plex human cytokine multiplex kits (Bio-Rad ILc. | 66 patients with CRC and 87 healthy controls | multiplex bead array immunoassay (Millipore) | Serum levels of IL-4 were higher in CRC patients. | 96 |
|--|--|--|--|-----|
| 105 CRC patientsELISAThe serum levels of IL-4 can be used as a marker of pre-invasive to invasive CRC.9910 CRC patients withFlow cytometricHigher serum levels of IL-4 were found in munophenotypingpatients than controls. The CD8+ cytotoxic cells99 CRC patients andELISAIL-4 serum levels of IL-4 were found in might be negatively regulated by serum IL-4.99 CRC patientsfluorescent bead-basedNo IL-4 expression was detected in serum, detection assay, anormal mucosa or tumor tissue.101107 healthy controlsmultiplex kit10220 CRC cellsRT-PCR, WB, FCM, in L-4 could increase the expression of survivin by attanswell assay, FCM, activating STAT6.103patients; nude miceFCR analysisresistance in primary human CC cells and T84104cells and T84 cellsPCR analysisresistance in primary human CC cells and T84105rof our CRCwith RNA-SeqCD133(-) CRC cells103patientsinsuccion of IL-4 was significantly up- regulated in CD133(+) cells compared to infiltrating cells associated IL-4 was responsible for weak immunogenicity in vitro, mice10590 remary CR cells, patientsImmunofluorescence infiltrating lymphocytes was associated with better prognosis.10541 metastatic CRC patientsBio-Plex humanThe aptression of IL-4 was ingrificantly in vitro, responsible for weak immunogenicity in vitro, mice10641 metastatic CRC patientsBio-Plex humanFCR cells, infiltrating lymphocytes was associated with | - | | - | 97 |
| liver metastases and 5 healthy controlsimmunophenotyping might be negatively regulated by serum IL-4.99 CRC patients and 107 healthy controlsELISAIL-4 serum levels were significantly higher in patients.100107 healthy controlsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue. Multiplex kit101Primary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, patients; nude miceIL-4 could increase the expression of survivin by activating STAT6.103Primary human CCFCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.104Primary and metastatic tumors from four CRCMagSweeper, whole- transcriptome analysisThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells105Primary CRC cells, NOD/SCID CB-17Immunofluorescence analysis, ELISA, miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity in vitro.10641 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have torgenosis.10741 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have torgenosis.10780 CRC patients and 33 matched controlsFuex haves cytokine Kit II (BD Biosciences)IL-4 was measured from the supernatants of noticancer vaccine.107 <td>•</td> <td>ELISA</td> <td>The serum levels of IL-4 can be used as a marker</td> <td>98</td> | • | ELISA | The serum levels of IL-4 can be used as a marker | 98 |
| 5 healthy controlsmight be negatively regulated by serum IL-4.99 CRC patients and 107 healthy controlsELISAIL-4 serum levels were significantly higher in patients.100107 healthy controlsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue.101Primary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, activating STAT6.IL-4 could increase the expression of survivin by activating STAT6.102patients; nude miceTUNEL stainingTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cellsFCR, analysis resistance in primary human CC cells and T84 cells.103Primary and metastatic tumors from four CRCMagSweeper, whole- with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to responsible for weak immunogenicity <i>in vitro</i> .105Primary CC cells, Immunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10541 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide infiltrating lymphocytes was associated with better prognosis.10743 matched controlsCytokine Kit II (BD Sinceres)Airger overall survival when receiving the thymidylate synthase poly-epitope-peptide infiltrating lymphocytes was found.10844 metastatic CRC patientsBio-Plex human cyt | 10 CRC patients with | Flow cytometric | Higher serum levels of IL-4 were found in | 99 |
| 99 CRC patients and 107 healthy controlsELISAIL-4 serum levels were significantly higher in patients.100107 healthy controlsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue. Autivating STAT6.101Primary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, activating STAT6.IL-4 could increase the expression of survivin by activating STAT6.102Primary human CCFCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary and from four CRCMagSweeper, whole- with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to responsible for weak immunogenicity <i>in vitro.</i> 105Primary CC cells, Immunofluorescence analysis, ELISA, miceImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro.</i> 10541 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide anticancer vaccine.10780 CRC patients and S8 matched controlsCytokine Kit II (BD Giosciences)Inoger overall survival when receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.10880 atched controlsCytokine Kit II (BD Giosciences)Aid weat sequence form the supernatants of ativated peripheral blood mononuclear cells.108 <t< td=""><td></td><td>immunophenotyping</td><td></td><td></td></t<> | | immunophenotyping | | |
| 107 healthy controlspatients.20 CRC patientsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue.101Primary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, patients; nude miceIL-4 could increase the expression of survivin by activating STAT6.102Primary human CCFCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary numMagSweeper, whole- transcriptome analysis with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to responsible for weak immunogenicity <i>in vitro</i> .104Primary CRC cells, noceImmunofluorescence analysis, ELISA, miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10541 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCExpression of IL-4 was measured from the supernatants of thymidylate synthase poly-epitope-petide thymidylate synthase poly-epitope-petide thymidylate synthase poly-epitope-petide10780 CRC patients and 38 matched controlsCytokine Kit II (BD Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10880 cRC patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total10890 return to the course of the supernatants of to subcutaneousIL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.108< | - | FLISΔ | | 100 |
| 20 CRC patientsfluorescent bead-based detection assay, Multiplex kitNo IL-4 expression was detected in serum, normal mucosa or tumor tissue. No RA construction to the superssion of survivine by activating STAT6.101Primary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, patients; nude miceIL-4 could increase the expression of survivine by activating STAT6.102Primary human CCFCM, IHC, Real-time FCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84103Primary and metastatic tumorsMagSweeper, whole- transcriptome analysis from four CRCThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104Primary CRC cells, NOD/SCID CB-17 miceImmunofluorescence subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity in vitro.10541 metastatic CRC patientsBio-Plex human cytokine multiplex kit (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have torigen overall survival when receiving the thymidylate synthase poly-epitope-petide thymidylate synthase poly-epitope-petide thymidylate synthase poly-epitope-petide10880 CRC patients and Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10880 SRC patients at Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10880 SRC patients at Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. <td>-</td> <td></td> <td></td> <td>100</td> | - | | | 100 |
| Multiplex kitPrimary CC cellsRT-PCR, WB, FCM, transwell assay, FCM, patients; nude miceIL-4 could increase the expression of survivin by activating STAT6.102patients; nude miceTUNEL stainingTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary numan CCPCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary andMagSweeper, whole- transcriptome analysisThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104patientsresult RNA-SeqCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .105NOD/SCID CB-17analysis, ELISA, model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10649 primary CC and patientsIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10741 metastatic CRC patientsBio-Plex human (bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have infiltrating lymphocytes was associated with better prognosis.10843 CRC patients and 38 matched controsHuman Th1/Th2IL-4 was measured from the supernatants of infiltrating level patients with higher serum IL-4 levels have infiltrating level patients as found.10840 primary CC and patientsHuman Th1/Th2IL-4 was measured from the supernatants of infiltrating level patients with higher serum IL-4 levels have <b< td=""><td>2</td><td>fluorescent bead-based</td><td></td><td>101</td></b<> | 2 | fluorescent bead-based | | 101 |
| isolated from 18 patients; nude mice primary human CC cells and T84 cellstranswell assay, FCM, TUNEL staining FCM, IHC, Real-time PCR analysisactivating STAT6.Primary human CC cells and T84 cellsFCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary and metastatic tumors from four CRC patientsMagSweeper, whole- transcriptome analysis with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104Primary CRC cells, NOD/SCID CB-17 miceImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10741 metastatic CRC patientsBio-Plex human (cytokine multiplex kits (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide (hymidylate synthase poly-epitope-peptide (hymidylate synthase poly-epitope-peptide (bioreand IL-1)10838 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells. Biosciences)10838 matched controlsELISA, EFA ingestionLong-term EFA ingestion could reduce total108 | | • | normal mucosa or tumor tissue. | |
| patients; nude mice Primary human CC cells and T84 cellsTUNEL staining FCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis resistance in primary human CC cells and T84 cells.103Primary and metastatic tumors from four CRC patientsMagSweeper, whole- transcriptome analysis with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104Primary CRC cells, NOD/SCID CB-17 miceImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10741 metastatic CRC patientsBio-Plex human (Bio-Rad Inc.), FACS, (Bio-Rad Inc.), FACS, (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have tonger overall survival when receiving the thymidylate synthase poly-epitope-peptide thymidylate synthase poly-epitope-peptide IHC10838 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells. Biosciences1089 tents with CRCELISA, EFA ingestionL-4 was function difference was found.108 | Primary CC cells | RT-PCR, WB, FCM, | IL-4 could increase the expression of survivin by | 102 |
| Primary human CC cells and T84 cellsFCM, IHC, Real-time PCR analysisTumor-cell-derived IL-4 enhanced apoptosis103Primary and metastatic tumorsMagSweeper, whole- transcriptome analysisThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104patientsmmunofluorescence model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .105NOD/SCID CB-17 miceanalysis, ELISA, model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10620 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10741 metastatic CRC patientsBio-Plex human (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide anticancer vaccine.10880 CRC patients and 38 matched controlsHuman Th1/Th2 Cytokine Kit II (BD Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10898 matched controlsCytokine Kit II (BD Biosciences)No significant difference was found.10898 matched controlsELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | • | activating STAT6. | |
| cells and T84 cellsPCR analysisresistance in primary human CC cells and T84 cells.Primary and metastatic tumors from four CRCMagSweeper, whole- transcriptome analysis with RNA-SeqThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104Primary CRC cells, NOD/SCID CB-17Immunofluorescence analysis, ELISA, miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex human (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide anticancer vaccine.10780 CRC patients and 38 matched controlsHuman Th1/Th2 Cytokine Kit II (BD Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. No significant difference was found.108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | - | 0 | Towns all daired II. As the set of second second set | 102 |
| Primary and metastatic tumorsMagSweeper, whole- transcriptome analysisThe expression of IL-4 was significantly up- regulated in CD133(+) cells compared to CD133(-) CRC cells104patientswith RNA-SeqCD133(-) CRC cells105patientsImmunofluorescence analysis, ELISA,Cancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .105NOD/SCID CB-17analysis, ELISA, analysis, ELISA,Cancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .105Model of miceIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10620 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.107patientsBio-Plex human (Bio-Rad Inc.), FACS, IHCIndecare vaccine.10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. Biosciences)10838 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells. No significant difference was found.108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | | | 103 |
| metastatic tumors from four CRC patientstranscriptome analysis with RNA-Seqregulated in CD133(+) cells compared to CD133(-) CRC cellsPrimary CRC cells, NOD/SCID CB-17 miceImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex human cytokine multiplex kits (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide thymidylate synthase poly-epitope-peptide anticancer vaccine.10880 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. Biosciences)108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | 1 Cix analysis | | |
| from four CRC patientswith RNA-SeqCD133(-) CRC cellsPrimary CRC cells, NOD/SCID CB-17 miceImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex human (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have hom gen overall survival when receiving the thymidylate synthase poly-epitope-peptide infiltrating level prognosic.10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of cytokine Kit II (BD Biosciences)10880 cRC patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total108 | Primary and | MagSweeper, whole- | The expression of IL-4 was significantly up- | 104 |
| patientsImmunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex human (Bio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have hymidylate synthase poly-epitope-peptide thymidylate synthase poly-epitope-peptide IHC10880 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. Biosciences)108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | metastatic tumors | transcriptome analysis | regulated in CD133(+) cells compared to | |
| Primary CRC cells, NOD/SCID CB-17Immunofluorescence analysis, ELISA, subcutaneous tumor model of miceCancer-initiating cells associated IL-4 was responsible for weak immunogenicity <i>in vitro</i> .10549 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex human (Kio-Rad Inc.), FACS, IHCThe patients with higher serum IL-4 levels have thymidylate synthase poly-epitope-peptide anticancer vaccine.10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of Cytokine Kit II (BD Biosciences)1089atients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | from four CRC | with RNA-Seq | CD133(-) CRC cells | |
| NOD/SCID CB-17analysis, ELISA, subcutaneous tumor model of miceresponsible for weak immunogenicity <i>in vitro</i> .49 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex humanThe patients with higher serum IL-4 levels have (Bio-Rad Inc.), FACS, IHC10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of Activated peripheral blood mononuclear cells. Biosciences)10894 Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | | | |
| micesubcutaneous tumor model of miceindel of mice10649 primary CC and 20 metastasesIHCExpression of IL-4 by > or $= 20\%$ of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRCBio-Plex humanThe patients with higher serum IL-4 levels have longer overall survival when receiving the thymidylate synthase poly-epitope-peptide thymidylate synthase poly-epitope-peptide IHC10780 CRC patients and 38 matched controlsHuman Th1/Th2 Cytokine Kit II (BD Biosciences)IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | • | | - | 105 |
| Image: horder of miceimage: horder of mi | | 5 | responsible for weak immunogenicity in other. | |
| 49 primary CC and 20 metastasesIHCExpression of IL-4 by > or = 20% of CC tumor infiltrating lymphocytes was associated with better prognosis.10641 metastatic CRC patientsBio-Plex humanThe patients with higher serum IL-4 levels have (bio-Rad Inc.), FACS, IHCIndicar overall survival when receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells. Biosciences)108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | mille | | | |
| 41 metastatic CRCBio-Plex humanThe patients with higher serum IL-4 levels have107patientscytokine multiplex kitslonger overall survival when receiving the107(Bio-Rad Inc.), FACS,longer overall survival when receiving the107IHCanticancer vaccine.10838 matched controlsCytokine Kit II (BDactivated peripheral blood mononuclear cells.Biosciences)No significant difference was found.109 | 49 primary CC and | | Expression of IL-4 by > or = 20% of CC tumor | 106 |
| 41 metastatic CRCBio-Plex humanThe patients with higher serum IL-4 levels have107patientscytokine multiplex kits (Bio-Rad Inc.), FACS, IHClonger overall survival when receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.10780 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10880 CRC patients and Biosciences)Cytokine Kit II (BD)activated peripheral blood mononuclear cells.1089 Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | 20 metastases | | infiltrating lymphocytes was associated with | |
| patientscytokine multiplex kits (Bio-Rad Inc.), FACS, IHClonger overall survival when receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.80 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10880 CRC patients and Biosciences)No significant difference was found.109Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | | better prognosis. | |
| (Bio-Rad Inc.), FACS, IHCthymidylate synthase poly-epitope-peptide anticancer vaccine.80 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10836 Desciences)Biosciences)No significant difference was found.109Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | 41 metastatic CRC | | The patients with higher serum IL-4 levels have | 107 |
| IHCanticancer vaccine.80 CRC patients andHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10838 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells.108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | patients | | 0 | |
| 80 CRC patients and 38 matched controlsHuman Th1/Th2IL-4 was measured from the supernatants of activated peripheral blood mononuclear cells.10838 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells.108Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | | | | |
| 38 matched controlsCytokine Kit II (BD Biosciences)activated peripheral blood mononuclear cells.No significant difference was found.Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | 90 CPC mation to an d | | | 100 |
| Biosciences)No significant difference was found.Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | - | | | 108 |
| Patients with CRCELISA, EFA ingestionLong-term EFA ingestion could reduce total109 | communed controls | | | |
| | Patients with CRC | , | - | 109 |
| | | | | |

Cell lines mentioned in this table are all human CC cell lines unless otherwise indicated. CRC: colon and rectal cancer; CC: colon cancer; FCM: flow cytometry; ELISA: enzyme-linked immunosorbent assay; WB: Western blot; IHC: immunohistochemistry; FAM120A: family with sequence similarity 120A; RT-PCR:

MTT: 3-(4,5-Dimethylthiazol-2-yl)reverse transcription-polymerase chain reaction; 2,5diphenyltetrazoliumbromid; 11βHSD2: 11β-hydroxysteroid dehydrogenase type II; IP: immunoprecipitation; qRT-PCR: quantitative real-time PCR; NOD/SCID: nonobese diabetic/severe combined immunodeficiency; CSC: cancer stem cell; FACS: fluorescence-activated cell sorting; Th: T helper; EFA: essential fatty acids.

| First author | Country | Ethnicity | Number of | SNPs | Result |
|---------------------------------|-----------------------|------------------------------|----------------|--|---|
| (year) | | | cases/controls | | |
| El-Omar (2003) (116) | USA | Mixed | 112/209 | IL-4 (-590 C/T), rs2243250 | No significant association |
| (116) Wu (2003) (117) | China | Asian | 220/230 | IL-4, rs2243250; IL-4R, rs1805010; IL- 4R, rs1801275 | Higher risk of developing diffuse type or cardia type cancer was observed for the CT/CC genotype of IL-4 at the position -590 (rs2243250). |
| Lai (2005) (118) | China | Asian | 123/162 | IL-4 (-590), rs2243250 | No significant association |
| Garcia-Gonzalez (2007) (119) | Spain | Caucasian | 404/404 | IL-4 (-590 C>T), rs2243250 | No significant association |
| Crusius (2008) | 10 | Caucasian | 235-244/1107- | IL-4, rs2243250; IL-4, rs2070874; | Rs2057768 is related with non-cardia gastric |
| (120) | European countries | | 1160 | IL-4R, rs1805010; IL-4R, rs2057768 | adenocarcinoma. |
| Zambon (2008) (121) | Italy | Caucasian | 144/171 | IL-4 -588C>T, rs2243250; IL-4RA Ex5+14A>G, rs1805010; IL-4RA Ex11+828A>G, rs 1801275 | No significant association |
| Ando (2009) (122) | Japan | Asian | 330/190 | IL-4 -590C/T; IL-4Rα Ile50Val | No significant association |
| Ko (2009) (123) | Korea | Asian | 78-81/320-324 | rs2070874; rs2243250 | No significant association |
| Wu (2009) (124) | China | Han Chinese population | 1042/1099 | rs2070874 | Compared with the IL-4 -168TT genotype, heterozygou -168TC and combined -168TC/CC genotypes were associated with a significantly decreased GC risk. |
| Pan (2014) (125) | China | Asian | 308/307 | rs2243250 | No significant association |

Supplemental Table 4. Polymorphisms of IL-4/IL-13 and their receptors in GC

| Yin (2015) (126) | China | Asian | 234/465 | IL-13, rs1800925 | No significant association with gastric cardiac adenocarcinoma risk |
|---------------------------------------|----------|------------|-------------|--|--|
| Cárdenas (2018) (45) | Colombia | Mixed | 15-17/20-30 | IL-4 -590 (C/T), IL-4 Ile50Val, IL-4 Q576R | No significant association |
| Martínez- Campos C (2019) (127) | Mexico | Mixed | 124/125 | IL-4-590C/T (rs2243250) | No significant association |
| He B (2019) (128) | China | Asian | 479/483 | IL-4 rs2243248; IL-4 rs2070874; IL-4R rs2057768; IL-4R rs2107356; IL-4R rs1805015; IL-4R rs1801275 | No significant association |
| Yun Y (2017) (129) | China | Asian | 340/364 | IL-4 rs2243250 (590 C/T), rs2227284 (107 T/C), rs2070874 (168 T/C) and rs1801275 (576 Q/R) | The IL-4 rs2243250 CC genotype and CT+CC genotype were associated with higher GC risk. |
| Burada F (2012) (130) | Romania | Caucasian | 105/242 | IL-4R -3223C→T, rs2057768 | IL-4R −3223C \rightarrow T polymorphism may increase the risk of gastric adenocarcinoma, mainly for the noncardia type. |
| Xia HZ (2012) (131) | China | Asian | 308/425 | IL-4R, rs2107356(G>A) | A significant reduction of the IL-4R AA genotype in GC risk was found when compared to GG genotype. |
| Bhayal AC (2015) (132) | India | Asian | 182/326 | IL-4 intron 3 variable number of tandem repeat (VNTR) | The study revealed an association of 2R allele and 2R carrier genotypes in the etiopathogenesis of GC. |
| Sampaio AM (2015) (133) | Portugal | Portuguese | 100/50 | IL-4 (-1098T>G), rs2243248; IL-4 (- 590C>T), rs2243250; IL-4 (-33C>T), rs2070874 | IL-4-590TT and IL-4-1098GG were found associated with intestinal type GC and diffuse type GC, respectively. IL- 4 TTT haplotype was linked with both intestinal and diffuse type GC groups. |
| Seno H (2007) (134) | Japan | Asian | 100/93 | IL-4 (11 SNPs), IL-4R (22 SNPs) | The IL-4 gene diplotypes are negatively associated with the risk of developing GC due to Helicobacter pylori infection. |

| Wang Y (2017) (135) | China | Asian | 362/384 | IL-4, rs2243248 (-1098 G/T), rs2227284 (-33 C/T), rs2243250 (-589 T/C) and rs2070874 (-107 T/C) | The TC and CC genotypes of rs2243250 were associated with an increased risk of GC. The TTTT haplotype revealed a reduced risk of GC. |
|------------------------------------|-----------|-----------|---------------------|---|--|
| Pavithra D (2018) (136) | India | Asian | 200/400 | IL-4C-590-T | No significant association |
| Cavalcante (2017) (137) | Brazil | Mixed | 119/474 | IL-4, rs79071878, VNTR | rs79071878 was positively associated with the development of GC. |
| Sarah Yang (2017) (138) | Korea | Asian | 368-377/736- 754 | IL-4R (rs7205663 and rs1805010); IL-13 (rs6596090, rs20541) | No significant association |
| Wang YM (2016) (139) | China | Asian | 132/1198 | IL-4R rs2057768 | No significant association |
| Schmidt HM (2011) (140) | Singapore | Asian | 60/162 | IL-13, rs1800925; IL-4, rs2070874; IL- 4R, rs1801275. | No significant association |
| García-González MA (2012) (141) | Spain | Caucasian | 380/- | IL-4, rs2243250 | Not relevant in determining the prognosis of gastric adenocarcinoma |
| Talebkhan Y (2017) (142) | Iran | Caucasian | 31/46 | IL-4 C-590T | Serum antibodies against Helicobacter pylori neutrophil activating protein in carriers of IL-4 C-590T genetic polymorphism amplify the risk of GC. |

GC: gastric cancer; SNPs: single nucleotide polymorphisms.

| First author | Country | Ethnicity | Number of | SNPs | Result |
|------------------|------------|------------|----------------|---------------------------------|--|
| (year) | | | cases/controls | | |
| Walczak A | Poland | Caucasian | 150/170 | IL-13, rs1800925 | The CT genotype is connected with a higher risk of colon |
| (2011) (143) | | | | | cancer occurrence. |
| Ibrahimi M | Iran | Iranian | 123/152 | IL-4 VNTR, RP1/RP1, RP1/RP2 | No significant association |
| (2019) (144) | | | | | |
| Landi S (2007) | Spain | Caucasian | 377/326 | IL-4 (-588C>T, Ex1-168G>A); IL- | The homozygotes for IL-4 -588C>T or for Ex1-168G>A |
| (145) | - | | | 4R (I75V, C431R, S436L, S503P, | showed an increased risk for colon cancer. Women |
| | | | | Q576R) | showed an increased risk associated to the IL-4 rare |
| | | | | | alleles. |
| Lee YS (2009) | Korea | Asian | 170/130 | IL-4R 1902 | The IL-4R 1902*T allele was found to be |
| (146) | | | · | | associated with an increased risk of colon cancer and |
| (-) | | | | | rectal cancer, while IL-4R 1902*C allele was associated |
| | | | | | with a decreased risk. |
| Cavalcante GC | Brazil | Mixed | 63/474 | IL-4, rs79071878, VNTR | No significant association |
| (2017) (137) | DIazii | Witzed | 00/1/1 | 11-4, 137 507 107 0, VINIK | No significant association |
| Jose M Cozar | Spain | Caucasian | 96/176 | IL-4-590 C>T (rs2243250) | No significant association |
| - | Span | Caucasian | 90/170 | IL-4-390 C/1 (152243230) | No significant association |
| (2007) (147) | Dolond | Coursesion | (07/250 | H_{-4} (500 C/T) | NIs significant according |
| Suchy (2008) | Poland | Caucasian | 607/350 | IL-4 (-590 C/T) | No significant association |
| (148) | C 1 | - · | 200/505 | | |
| Wilkening (2008) | Sweden | Caucasian | 308/585 | IL-4-590C/T (rs2243250); IL-4R- | The rare T allele of IL-4-590 was related to a longer |
| (149) | | | | 3223G/A (rs2057768) | survival. The prognostic value of the genotypes was of |
| | | | | | borderline significance. |

Supplemental Table 5. Polymorphisms of IL-4/IL-13 and their receptors in colorectal cancer (CRC)

| Levar Shamoun (2018) (150) | Sweden | Caucasian | 466/445 | IL-4, rs2243250; IL-4Rα, rs1801275; IL-13, rs1800925 | IL-13 SNP rs1800925 is a risk factor for CRC and that IL-4 SNP rs2243250 could be a useful prognostic marker. |
|----------------------------------|-------------------|-----------|----------|---|--|
| Yanming Yu (2017) (151) | China | Asian | 513/572 | IL-13: rs847 A>G; IL-13: rs848 T>G; IL-13: rs1295685 C>T | A significant antagonistic interaction was found between rs848 (G-T) and allium vegetable intake; moreover, significant combined and synergistic interactions were observed for all three SNPs and overnight meal intake. |
| Y Yu (2014) (152) | China | Asian | 299/296 | IL-4 rs2070874 | No significant association |
| Diego Marques (2017) (153) | Brazil | Mixed | 140/140 | IL-4 rs79071878 | Polymorphism variations in IL-4 gene was associated with increased CRC risk. |
| Walczak A (2012) (154) | Poland | Caucasian | 191/205 | IL-13 - 1112 C/T, rs1800925 | The CT and TT genotypes of the IL-13 - 1112 C/T polymorphism may be connected with a higher risk of CRC. |
| Raul Zamora- Ros (2015) (155) | Spain | Caucasian | 274/266 | IL-4, rs2243250 | The novel dietary inflammatory index (DII) score was inversely correlated with SNP rs2243250, and an interaction was observed with CRC risk. |
| Xiulin Wen (2020) (156) | China | Asian | 248/463 | IL-4, rs2243250 and rs2227284 | rs2243250 and rs2227284 in IL-4 are associated significantly with reduced CRC risk. |
| Nicola Ingram (2013) (62) | United Kingdom | Caucasian | 1502/584 | IL-4Rα: rs1801275, rs1805015, rs1805016, rs1805013, rs1805011, rs1805010. | SNP rs1801275 was associated with increased CRC risk. Reduced IL-4R signalling was associated with increased CRC initiation and risk but reduced tumour progression and no effect on CRC mortality. |
| Florin Burada (2013) (157) | Romania | Caucasian | 144/233 | IL-4R -3223C > T | No significant association |
| Yannopoulos (2007) (158) | Greece | Caucasian | 93/108 | IL-4 (-590 C/T) | The (–590 C/T) polymorphism in the IL-4 gene is associated with increased risk for early stages of colorectal adenocarcinoma. |

| Bente A Talseth | Poland | Caucasian | 118/100 | IL-4 C-589T (rs2243250) | No significant association between SNP rs2243250 and |
|-----------------|---------|-----------|-----------|----------------------------------|--|
| (2007) (159) | | | | | hereditary non-polyposis CRC. |
| Juan Sainz | Germany | Caucasian | 1798/1810 | IL-13, rs20541 | Patients harboring the IL-13_rs20541_T allele had a |
| (2012) (160) | | | | | reduced risk of CRC. |
| Lin Xiao (2016) | China | Asian | 58/- | IL-13, 1112 C/T (rs1800925) | The studied SNP does not predict responsiveness to |
| (161) | | | | | neoadjuvant chemoradiotherapy or prognosis of locally |
| | | | | | advanced rectal cancer. |
| A Ho-Pun- | France | Caucasian | 71/- | IL-4, rs2243250; IL-13, rs20541, | The SNP IL-13 rs1800925 was significantly associated |
| Cheung (2011) | | | | rs1800925 | with rectal adenocarcinoma response to chemoradiation. |
| (162) | | | | | |

CRC: colon and rectal cancer; SNPs: single nucleotide polymorphisms.